Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Change in Accured Expenses for 8 consecutive years, with -$7.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 38.33% year-over-year to -$7.2 million; the TTM figure through Mar 2026 stood at $11.9 million (up 50.53% YoY), while the FY2025 annual figure was $7.4 million, up 76.72% from the prior year.
• Change in Accured Expenses retreated to -$7.2 million in Q1 2026 per KYMR's latest filing, from $13.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $13.7 million in Q4 2025 and bottomed at -$15.4 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $709235.3 across 5 years, with a median of $2.7 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 1069.36% — and 2023, when it soared 578.32%.
• Kymera Therapeutics' Change in Accured Expenses stood at $2.8 million in 2022, then soared by 139.02% to $6.8 million in 2023, then surged by 32.81% to $9.0 million in 2024, then surged by 51.43% to $13.7 million in 2025, then sank by 152.77% to -$7.2 million in 2026.
• Business Quant data shows KYMR's Change in Accured Expenses at -$7.2 million in Q1 2026, $13.7 million in Q4 2025, and $664000.0 in Q3 2025.